{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:22:43Z","timestamp":1792783363964,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Science & Technology Department of Sichuan Province","award":["2024YFFK0025"],"award-info":[{"award-number":["2024YFFK0025"]}],"id":[{"id":"https:\/\/ror.org\/04323m874","id-type":"ROR","asserted-by":"crossref"}]},{"name":"1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University","award":["23HXFH025"],"award-info":[{"award-number":["23HXFH025"]}],"id":[{"id":"https:\/\/ror.org\/011ashp19","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sichuan Province Nuclear Medicine Whole Industry Chain Breakthrough Project","award":["JG202507"],"award-info":[{"award-number":["JG202507"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04779-1","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:10:29Z","timestamp":1790575829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of RET fusions on radioiodine avidity and prognosis in patients with distant metastatic papillary thyroid cancer"],"prefix":"10.1007","volume":"91","author":[{"given":"Kexin","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3191-0528","authenticated-orcid":false,"given":"Rui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"4779_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1056\/NEJMra1501993","volume":"375","author":"JA Fagin","year":"2016","unstructured":"J.A. Fagin, S.A. Wells, Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med. 375, 1054\u20131067 (2016). https:\/\/doi.org\/10.1056\/NEJMra1501993","journal-title":"N. Engl. J. Med."},{"key":"4779_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2017.02.023","volume":"77","author":"L Dal Maso","year":"2017","unstructured":"L. Dal Maso, A. Tavilla, F. Pacini, D. Serraino, B.A.C. Van Dijk, M.D. Chirlaque et al. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5. Eur. J. Cancer. 77, 140\u2013152 (2017). https:\/\/doi.org\/10.1016\/j.ejca.2017.02.023","journal-title":"Eur. J. Cancer."},{"key":"4779_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1210\/jcem-67-3-501","volume":"67","author":"JJ Ruegemer","year":"1988","unstructured":"J.J. Ruegemer, I.D. Hay, E.J. Bergstralh, J.J. Ryan, K.P. Offord, C.A. Gorman, Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J. Clin. Endocrinol. Metab. 67, 501\u2013508 (1988). https:\/\/doi.org\/10.1210\/jcem-67-3-501","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4779_CR4","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1089\/thy.2004.14.1091","volume":"14","author":"J-D Lin","year":"2004","unstructured":"J.-D. Lin, T.-C. Chao, S.-C. Chou, C. Hsueh, Papillary thyroid carcinomas with lung metastases. Thyroid 14, 1091\u20131096 (2004). https:\/\/doi.org\/10.1089\/thy.2004.14.1091","journal-title":"Thyroid"},{"key":"4779_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(19880101)61:1<1::AID-CNCR2820610102>3.0.CO;2-R","volume":"61","author":"J H\u00f8ie","year":"1988","unstructured":"J. H\u00f8ie, A.E. Stenwig, G. Kullmann, M. Lindegaard, Distant metastases in papillary thyroid cancer.a review of 91 patients. Cancer. 61, 1\u20136 (1988). 10.1002\/1097-0142(19880101)61:1<1::AID-CNCR2820610102>3.0.CO;2-R","journal-title":"Cancer."},{"key":"4779_CR6","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"C. Durante, N. Haddy, E. Baudin, S. Leboulleux, D. Hartl, J.P. Travagli et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91, 2892\u20132899 (2006). https:\/\/doi.org\/10.1210\/jc.2005-2838","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4779_CR7","first-page":"1519","volume":"4","author":"Y Ishizaka","year":"1989","unstructured":"Y. Ishizaka, F. Itoh, T. Tahira, I. Ikeda, T. Sugimura, J. Tucker et al. Human ret proto-oncogene mapped to chromosome 10q11.2. Oncogene 4, 1519\u20131521 (1989)","journal-title":"Oncogene"},{"key":"4779_CR8","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","volume":"16","author":"E Arighi","year":"2005","unstructured":"E. Arighi, M.G. Borrello, H. Sariola, RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor. Rev. 16, 441\u2013467 (2005). https:\/\/doi.org\/10.1016\/j.cytogfr.2005.05.010","journal-title":"Cytokine Growth Factor. Rev."},{"key":"4779_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","volume":"20","author":"I Landa","year":"2024","unstructured":"I. Landa, M.E. Cabanillas, Genomic alterations in thyroid cancer: biological and clinical insights. Nat. Rev. Endocrinol. 20, 93\u2013110 (2024). https:\/\/doi.org\/10.1038\/s41574-023-00920-6","journal-title":"Nat. Rev. Endocrinol."},{"key":"4779_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11154-023-09840-2","volume":"25","author":"MSA de Sousa","year":"2024","unstructured":"M.S.A. de Sousa, I.N. Nunes, Y.P. Christiano, L. Sisdelli, J.M. Cerutti, Genetic alterations landscape in paediatric thyroid tumours and\/or differentiated thyroid cancer: systematic review. Rev. Endocr. Metab. Disord. 25, 35\u201351 (2024). https:\/\/doi.org\/10.1007\/s11154-023-09840-2","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"4779_CR11","doi-asserted-by":"publisher","unstructured":"T.M. Ullmann, J.W. Thiesmeyer, Y.J. Lee, S. Beg, J.M. Mosquera, O. Elemento et al., RET fusion-positive papillary thyroid cancers are associated with a more aggressive phenotype. Ann. Surg. Oncol. 29, 4266\u20134273 (2022). https:\/\/doi.org\/10.1245\/s10434-022-11418-2","DOI":"10.1245\/s10434-022-11418-2"},{"key":"4779_CR12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1089\/thy.2019.0802","volume":"30","author":"B Pekova","year":"2020","unstructured":"B. Pekova, V. Sykorova, S. Dvorakova, E. Vaclavikova, J. Moravcova, R. Katra et al. RET, NTRK, ALK, BRAF, and MET fusions in a large cohort of pediatric papillary thyroid carcinomas. Thyroid 30, 1771\u20131780 (2020). https:\/\/doi.org\/10.1089\/thy.2019.0802","journal-title":"Thyroid"},{"key":"4779_CR13","doi-asserted-by":"publisher","first-page":"e230117","DOI":"10.1530\/erc-23-0117","volume":"30","author":"B Bulanova Pekova","year":"2023","unstructured":"B. Bulanova Pekova, V. Sykorova, K. Mastnikova, E. Vaclavikova, J. Moravcova, P. Vlcek et al., RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis. Endocr. Relat. Cancer. 30, e230117 (2023). https:\/\/doi.org\/10.1530\/erc-23-0117","journal-title":"Endocr. Relat. Cancer"},{"key":"4779_CR14","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.ejso.2018.11.009","volume":"45","author":"TJ Musholt","year":"2019","unstructured":"T.J. Musholt, J.I. Staubitz, R.J. Antonio C\u00e1mara, P.B. Musholt, D. Humberg, E. Springer et al. Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - a molecular and clinical analysis. Eur. J. Surg. Oncol. 45, 1018\u20131024 (2019). https:\/\/doi.org\/10.1016\/j.ejso.2018.11.009","journal-title":"Eur. J. Surg. Oncol."},{"key":"4779_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611138","volume":"29","author":"T Khonrak","year":"2023","unstructured":"T. Khonrak, S. Watcharadetwittaya, Y. Chamgramol, P. Intarawichian, R. Deenonpoe, RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients. Pathol. Oncol. Res. 29, 1611138 (2023). https:\/\/doi.org\/10.3389\/pore.2023.1611138","journal-title":"Pathol. Oncol. Res."},{"key":"4779_CR16","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1089\/thy.2024.0151","volume":"34","author":"Z Wang","year":"2024","unstructured":"Z. Wang, Q. Yao, L. Bao, H. Chang, M. Ren, T. Xue et al. Clinicopathological features of CCDC6-RET and NCOA4-RET fusions in thyroid cancer: a single-center retrospective cohort study in a Chinese population. Thyroid 34, 1260\u20131270 (2024). https:\/\/doi.org\/10.1089\/thy.2024.0151","journal-title":"Thyroid"},{"key":"4779_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0002-9440(10)64368-4","volume":"160","author":"F Basolo","year":"2002","unstructured":"F. Basolo, R. Giannini, C. Monaco, R.M. Melillo, F. Carlomagno, M. Pancrazi et al. Potent mitogenicity of the RET\/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. Am. J. Pathol. 160, 247\u2013254 (2002). https:\/\/doi.org\/10.1016\/S0002-9440(10)64368-4","journal-title":"Am. J. Pathol."},{"key":"4779_CR18","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1016\/j.celrep.2016.08.019","volume":"16","author":"S Levinson","year":"2016","unstructured":"S. Levinson, R.L. Cagan, Drosophila cancer models identify functional differences between ret fusions. Cell. Rep. 16, 3052\u20133061 (2016). https:\/\/doi.org\/10.1016\/j.celrep.2016.08.019","journal-title":"Cell. Rep."},{"key":"4779_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/eje.1.02257","volume":"155","author":"G Riesco-Eizaguirre","year":"2006","unstructured":"G. Riesco-Eizaguirre, P. Santisteban, A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol. 155, 495\u2013512 (2006). https:\/\/doi.org\/10.1530\/eje.1.02257","journal-title":"Eur. J. Endocrinol."},{"key":"4779_CR20","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"J.M. Oh, B.C. Ahn, Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11, 6251\u20136277 (2021). https:\/\/doi.org\/10.7150\/thno.57689","journal-title":"Theranostics"},{"key":"4779_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100939","volume":"68","author":"Y Liu","year":"2023","unstructured":"Y. Liu, J. Wang, X. Hu, Z. Pan, T. Xu, J. Xu et al. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy. Drug. Resist. Updat. 68, 100939 (2023). https:\/\/doi.org\/10.1016\/j.drup.2023.100939","journal-title":"Drug. Resist. Updat."},{"key":"4779_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1210\/en.2006-0921","volume":"148","author":"R Ciampi","year":"2007","unstructured":"R. Ciampi, Y.E. Nikiforov, RET\/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148, 936\u2013941 (2007). https:\/\/doi.org\/10.1210\/en.2006-0921","journal-title":"Endocrinology"},{"key":"4779_CR23","doi-asserted-by":"publisher","first-page":"6168","DOI":"10.1210\/jc.2004-1414","volume":"89","author":"A Venkateswaran","year":"2004","unstructured":"A. Venkateswaran, D.K. Marsee, S.H. Green, S.M. Jhiang, Forskolin, 8-Br-3\u2032,5\u2032-Cyclic Adenosine 5\u2032-Monophosphate, and catalytic protein kinase a expression in the nucleus increase radioiodide uptake and sodium\/iodide symporter protein levels in RET\/PTC1-expressing cells. J. Clin. Endocrinol. Metab. 89, 6168\u20136172 (2004). https:\/\/doi.org\/10.1210\/jc.2004-1414","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4779_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1530\/eje.0.1400447","volume":"140","author":"F Trapasso","year":"1999","unstructured":"F. Trapasso, R. Iuliano, E. Chiefari, F. Arturi, A. Stella, S. Filetti et al. Iodide symporter gene expression in normal and transformed rat thyroid cells. Eur. J. Endocrinol. 140, 447\u2013451 (1999). https:\/\/doi.org\/10.1530\/eje.0.1400447","journal-title":"Eur. J. Endocrinol."},{"key":"4779_CR25","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"M.D. Ringel, J.A. Sosa, Z. Baloch, L. Bischoff, G. Bloom, G.A. Brent et al. 2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 35, 841\u2013985 (2025). https:\/\/doi.org\/10.1177\/10507256251363120","journal-title":"Thyroid"},{"key":"4779_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1089\/thy.2017.0318","volume":"28","author":"VD Yakushina","year":"2018","unstructured":"V.D. Yakushina, L.V. Lerner, A.V. Lavrov, Gene fusions in thyroid cancer. Thyroid 28, 158\u2013167 (2018). https:\/\/doi.org\/10.1089\/thy.2017.0318","journal-title":"Thyroid"},{"key":"4779_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.101911","volume":"81","author":"AY Li","year":"2019","unstructured":"A.Y. Li, M.G. McCusker, A. Russo, K.A. Scilla, A. Gittens, K. Arensmeyer et al. RET fusions in solid tumors. Cancer Treat. Rev. 81, 101911 (2019). https:\/\/doi.org\/10.1016\/j.ctrv.2019.101911","journal-title":"Cancer Treat. Rev."},{"key":"4779_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1200\/JCO.21.01861","volume":"40","author":"AT Franco","year":"2022","unstructured":"A.T. Franco, J.C. Ricarte-Filho, A. Isaza, Z. Jones, N. Jain, S. Mostoufi-Moab et al. Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers. JCO 40, 1081\u20131090 (2022). https:\/\/doi.org\/10.1200\/JCO.21.01861","journal-title":"JCO"},{"key":"4779_CR29","doi-asserted-by":"publisher","unstructured":"Lee Y.A., Lee H., Im S.W., Song Y.S., Oh D.Y., Kang H.J., et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J. Clin. Invest. https:\/\/doi.org\/10.1172\/jci144847","DOI":"10.1172\/jci144847"},{"key":"4779_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1210\/clinem\/dgad500","volume":"109","author":"G Ju","year":"2024","unstructured":"G. Ju, Y. Sun, H. Wang, X. Zhang, Z. Mu, D. Sun et al. Fusion oncogenes in patients with locally advanced or distant metastatic differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 109, 505\u2013515 (2024). https:\/\/doi.org\/10.1210\/clinem\/dgad500","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4779_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/ijo.2021.5193","volume":"58","author":"AB Zanella","year":"2021","unstructured":"A.B. Zanella, R.S. Scheffel, L. Weinert, J.M. Dora, A.L. Maia, New insights into the management of differentiated thyroid carcinoma in children and adolescents (Review). Int. J. Oncol. 58, 13 (2021). https:\/\/doi.org\/10.3892\/ijo.2021.5193","journal-title":"Int. J. Oncol."},{"key":"4779_CR32","doi-asserted-by":"publisher","first-page":"16716","DOI":"10.18632\/oncotarget.7574","volume":"7","author":"X Su","year":"2016","unstructured":"X. Su, Z. Li, C. He, W. Chen, X. Fu, A. Yang, Radiation exposure, young age, and female gender are associated with high prevalence of RET\/PTC1 and RET\/PTC3 in papillary thyroid cancer: a meta-analysis. Oncotarget 7, 16716\u201316730 (2016). https:\/\/doi.org\/10.18632\/oncotarget.7574","journal-title":"Oncotarget"},{"key":"4779_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3390\/genes11040424","volume":"11","author":"M Santoro","year":"2020","unstructured":"M. Santoro, M. Moccia, G. Federico, F. Carlomagno, RET gene fusions in malignancies of the thyroid and other tissues. Genes (Basel) 11, 424 (2020). https:\/\/doi.org\/10.3390\/genes11040424","journal-title":"Genes (Basel)"},{"key":"4779_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144611","volume":"746","author":"S Tural","year":"2020","unstructured":"S. Tural, M. Yuce, A. K Polat, E. Tekcan, B.Z. Celik, U. Karabacak, N. Kara et al. Novel RET Proto-oncogene variants identified in Turkish patients with thyroid carcinoma. Gene 746, 144611 (2020). https:\/\/doi.org\/10.1016\/j.gene.2020.144611","journal-title":"Gene"},{"key":"4779_CR35","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1089\/thy.2016.0673","volume":"27","author":"K Iyama","year":"2017","unstructured":"K. Iyama, M. Matsuse, N. Mitsutake, T. Rogounovitch, V. Saenko, K. Suzuki et al. Identification of three novel fusion oncogenes, SQSTM1\/NTRK3, AFAP1L2\/RET, and PPFIBP2\/RET, in thyroid cancers of young patients in Fukushima. Thyroid 27, 811\u2013818 (2017). https:\/\/doi.org\/10.1089\/thy.2016.0673","journal-title":"Thyroid"},{"key":"4779_CR36","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1111\/cas.14389","volume":"111","author":"X Lan","year":"2020","unstructured":"X. Lan, H. Bao, X. Ge, J. Cao, X. Fan, Q. Zhang et al. Genomic landscape of metastatic papillary thyroid carcinoma and novel biomarkers for predicting distant metastasis. Cancer Sci. 111, 2163\u20132173 (2020). https:\/\/doi.org\/10.1111\/cas.14389","journal-title":"Cancer Sci."},{"key":"4779_CR37","doi-asserted-by":"publisher","first-page":"e0165596","DOI":"10.1371\/journal.pone.0165596","volume":"11","author":"X Su","year":"2016","unstructured":"X. Su, C. He, J. Ma, T. Tang, X. Zhang, Z. Ye et al. RET\/PTC rearrangements are associated with elevated postoperative TSH levels and multifocal lesions in papillary thyroid cancer without concomitant thyroid benign disease. PLoS One 11, e0165596 (2016). https:\/\/doi.org\/10.1371\/journal.pone.0165596","journal-title":"PLoS One"},{"key":"4779_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/thy.2011.0215","volume":"22","author":"G Sassolas","year":"2012","unstructured":"G. Sassolas, Z. Hafdi-Nejjari, A. Ferraro, M. Decaussin-Petrucci, B. Rousset, F. Borson-Chazot et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid 22, 17\u201326 (2012). https:\/\/doi.org\/10.1089\/thy.2011.0215","journal-title":"Thyroid"},{"key":"4779_CR39","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12020-023-03633-y","volume":"84","author":"J Sim\u00f5es-Pereira","year":"2024","unstructured":"J. Sim\u00f5es-Pereira, A. Saramago, R. Rodrigues, M. Pojo, C. Pires, M. Horta et al. Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes. Endocrine 84, 625\u2013634 (2024). https:\/\/doi.org\/10.1007\/s12020-023-03633-y","journal-title":"Endocrine"},{"key":"4779_CR40","doi-asserted-by":"publisher","first-page":"4406","DOI":"10.1038\/sj.onc.1206602","volume":"22","author":"JA Knauf","year":"2003","unstructured":"J.A. Knauf, H. Kuroda, S. Basu, J.A. Fagin, RET\/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase. Oncogene 22, 4406\u20134412 (2003). https:\/\/doi.org\/10.1038\/sj.onc.1206602","journal-title":"Oncogene"},{"key":"4779_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1677\/erc.1.01263","volume":"14","author":"DD Vadysirisack","year":"2007","unstructured":"D.D. Vadysirisack, A. Venkateswaran, Z. Zhang, S.M. Jhiang, MEK signaling modulates sodium iodide symporter at multiple levels and in a paradoxical manner. Endocr. Relat. Cancer 14, 421\u2013432 (2007). https:\/\/doi.org\/10.1677\/erc.1.01263","journal-title":"Endocr. Relat. Cancer"},{"key":"4779_CR42","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1210\/jc.2014-3023","volume":"100","author":"M Ruan","year":"2015","unstructured":"M. Ruan, M. Liu, Q. Dong, L. Chen, Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. J. Clin. Endocrinol Metab. 100, 1771\u20131779 (2015). https:\/\/doi.org\/10.1210\/jc.2014-3023","journal-title":"J. Clin. Endocrinol Metab."},{"key":"4779_CR43","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1089\/thy.2010.0008","volume":"20","author":"MS Fenton","year":"2010","unstructured":"M.S. Fenton, K.M. Marion, A.K. Salem, R. Hogen, F. Naeim, J.M. Hershman, Sunitinib inhibits MEK\/ERK and SAPK\/JNK pathways and increases sodium\/iodide symporter expression in papillary thyroid cancer. Thyroid 20, 965\u2013974 (2010). https:\/\/doi.org\/10.1089\/thy.2010.0008","journal-title":"Thyroid"},{"key":"4779_CR44","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1089\/thy.2021.0144","volume":"31","author":"L Groussin","year":"2021","unstructured":"L. Groussin, L. Bessiene, J. Arrondeau, S. Garinet, B. Cochand-Priollet, A. Lupo et al. Letter to the editor: selpercatinib-enhanced radioiodine uptake in RET-rearranged thyroid cancer. Thyroid 31, 1603\u20131604 (2021). https:\/\/doi.org\/10.1089\/thy.2021.0144","journal-title":"Thyroid"},{"key":"4779_CR45","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-13-0210","volume":"20","author":"X Liu","year":"2013","unstructured":"X. Liu, J. Bishop, Y. Shan, S. Pai, D. Liu, A.K. Murugan et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr. Relat. Cancer 20, 603\u2013610 (2013). https:\/\/doi.org\/10.1530\/ERC-13-0210","journal-title":"Endocr. Relat. Cancer"},{"key":"4779_CR46","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","volume":"3","author":"R Liu","year":"2017","unstructured":"R. Liu, J. Bishop, G. Zhu, T. Zhang, P.W. Ladenson, M. Xing, Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality. JAMA Oncol. 3, 202 (2017). https:\/\/doi.org\/10.1001\/jamaoncol.2016.3288","journal-title":"JAMA Oncol."},{"key":"4779_CR47","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/cncr.29934","volume":"122","author":"YS Song","year":"2016","unstructured":"Y.S. Song, J.A. Lim, H. Choi, J. Won, J.H. Moon, S.W. Cho et al. Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients. Cancer 122, 1370\u20131379 (2016). https:\/\/doi.org\/10.1002\/cncr.29934","journal-title":"Cancer"},{"key":"4779_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03033-1","volume":"9","author":"R Liu","year":"2018","unstructured":"R. Liu, T. Zhang, G. Zhu, M. Xing, Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer. Nat. Commun. 9, 579 (2018). https:\/\/doi.org\/10.1038\/s41467-018-03033-1","journal-title":"Nat. Commun."},{"key":"4779_CR49","doi-asserted-by":"publisher","first-page":"15846","DOI":"10.1073\/pnas.2004707117","volume":"117","author":"J Tan","year":"2020","unstructured":"J. Tan, R. Liu, G. Zhu, C.B. Umbricht, M. Xing, TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel. Proc. Natl. Acad. Sci. USA 117, 15846\u201315851 (2020). https:\/\/doi.org\/10.1073\/pnas.2004707117","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4779_CR50","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1530\/ERC-17-0562","volume":"26","author":"YS Song","year":"2019","unstructured":"Y.S. Song, S.-K. Yoo, H.H. Kim, G. Jung, A.-R. Oh, J.-Y. Cha et al. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocr. Relat. Cancer. 26, 629\u2013641 (2019). https:\/\/doi.org\/10.1530\/ERC-17-0562","journal-title":"Endocr. Relat. Cancer."},{"key":"4779_CR51","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1210\/clinem\/dgae327","volume":"109","author":"W Zhang","year":"2024","unstructured":"W. Zhang, S. Lin, Z. Wang, W. Zhang, M. Xing, Coexisting RET\/PTC and TERT promoter mutation predict poor prognosis but effective RET and MEK targeting in thyroid cancer. J. Clin. Endocrinol. Metab. 109, 3166\u20133175 (2024). https:\/\/doi.org\/10.1210\/clinem\/dgae327","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4779_CR52","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1038\/s41379-020-0638-5","volume":"33","author":"Y-H Chu","year":"2020","unstructured":"Y.-H. Chu, L.J. Wirth, A.A. Farahani, V. Nos\u00e9, W.C. Faquin, D. Dias-Santagata et al. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Modern Pathology 33, 2458\u20132472 (2020). https:\/\/doi.org\/10.1038\/s41379-020-0638-5","journal-title":"Modern Pathology"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04779-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04779-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T06:10:31Z","timestamp":1790575831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04779-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4779"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04779-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Biomedical Ethics Review Committee of West China Hospital, Sichuan University (November 29, 2023\/ 2023-2091) which granted a waiver of informed consent owing to the retrospective nature of the study, and was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the retrospective design of this study and the use of anonymized clinical data, the requirement for individual informed consent was waived by the Biomedical Ethics Review Committee of West China Hospital, Sichuan University.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"308"}}